Stroke: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• NLRP3 0
• NRF2 0
• GLP-1 4
• PCSK9 12
• AKT 0
• PI3K 0
• SGLT2 2
• BDNF 2
• TLR4 0
• AMPK 0
• STAT3 0
• mTOR 0
• VEGF 0
• ERK 0
• HIF-1 0
• SIRT1 0
• PPAR 1
• STING 0
• GPX4 0
• MMP-9 0
• HMGB1 0
• IL-6 0
• APOE 0
• JAK 0
• NOTCH3 1
• MAPK 0
• NMDA 0
• TNF 0
• TP53 0
• DPP-4 1
• CTNNB1 0
• CXCR4 0
• IL-1 1
• TREM2 0
• FTO 0
• IL-17 0
• JNK 0
• COX-2 0
• PTEN 0
• PARP 0
• YAP 0
• AQP4 0
• CCR5 1
• BCL-2 0
• EGFR 0
• PINK1 0
• HSP90 0
• AR 0
• GIP 0
• HDAC 0
• PD-L1 0
• PDE4 0
• PDGFR 0
• TFEB 0
• ATM 0
• B7-H3 0
• CGRP 0
• FOXP3 0
• MAPT 0
• MEK 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  Understanding learning variability to personalise training and boost knowledge-driven, efficient and acceptable neurotechnologies (VARIABILITI)

  Universite de Bordeaux· Bordeaux, France· EU contribution €4,606,137· until Feb 2032· 11 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Supermassive Black Hole Transients: From Single Brush Strokes to the Entire Painting (BHFlares)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €2,053,750· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Human–robot Adaptive Role MOdulation with Neuro-inspired trajectorY (HARMONY)

  Scuola Universitaria Professionale Della Svizzera Italiana· Manno, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  From lab to life: measuring and modulating musculoskeletal load in human locomotion (MSKLOAD)

  Norges Idrettshogskole· Oslo, Norway· EU contribution €334,273· until Jun 2029· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Emerging risk factors for stroke: Deciphering the biological mechanisms underlying the impact of chronic stress on the microbiome and microglia epigenetics. (MicroStress)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €202,125· until Dec 2028

5 of 115 running projects, newest first. Listed amounts together: €396.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Long-term Prospective Study of Korean CADASIL Patients

  NCT07497867· Jeju National University Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 38
• Organoids 7
• Mendelian Randomization Analysis 168
• CRISPR-Cas Systems 4
• Gene Expression Profiling 74
• Sequence Analysis, RNA 12
• Exome Sequencing 8
• Proteomics 98
• Metabolomics 71
• Mass Spectrometry 12
• Flow Cytometry 12
• Immunohistochemistry 33
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 852
• Machine Learning 354
• Deep Learning 123
• Cohort Studies 943
• Genome-Wide Association Study 140

• Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as Well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde.

  Curr Cancer Drug Targets, Jan 2016

See which targets of this disease your abstract mentions, and go to the people working on them.